 |
Joint
Care eNews #8 / March 2008 |
| Joint Care Headlines | ||||
| BIOIBERICA
IS THE FIRST COMPANY TO OBTAIN THE CERTIFICATE OF SUITABILITY FOR
CHONDROITIN SULPHATE BIOIBERICA continues its international leadership by becoming the first company in the world to obtain the Certificate of Suitability for Chondroitin Sulphate Sodium. This certificate is awarded by the European Directorate for the Quality of Medicines & HealthCare (EDQM), the body of the Council of Europe that supervises and controls the composition and production of pharmaceutical substances to the strict standards of the European Pharmacopoeia in order to guarantee a quality framework for pharmaceutical active ingredients. (more) NEW FINDINGS ON HYAL-JOINT EFFICACY PRESENTED AT OARSI During the last World Congress of the Osteoarthritis Research Society International (OARSI) held on December 6-9, 2007 in Fort Lauderdale, Florida, BIOIBERICA presented a poster with its new findings on Hyal-Joint efficacy, which suggest that oral administration of hyaluronic acid (HA) increases HA levels in synovial fluid and could also be related to improvements in the clinical condition of affected joints. (more) BIOIBERICA AT THE WORLD CONGRESS ON OSTEOARTHRITIS (OARSI) As part of its program of continued research into the efficacy of Chondroitin Sulfate (CS) in the treatment of synovitis, BIOIBERICA sponsored a symposium on The Role of Synovitis in the Physiopathology of Osteoarthritis: New Effects of Chondroitin Sulfate at the most recent World Congress on Osteoarthritis (OARSI), held in Fort Lauderdale, Florida, on December 6-9, 2007. (more) |
||||
|
| ||||
| Joint Care News | ||||
| BIOIBERICA IS THE FIRST COMPANY TO OBTAIN THE
CERTIFICATE OF SUITABILITY FOR CHONDROITIN
SULPHATE BIOIBERICA continues its international leadership by becoming the first company in the world to obtain the Certificate of Suitability for Chondroitin Sulphate Sodium. This certificate is awarded by the European Directorate for the Quality of Medicines & HealthCare (EDQM), the body of the Council of Europe that supervises and controls the composition and production of pharmaceutical substances to the strict standards of the European Pharmacopoeia in order to guarantee a quality framework for pharmaceutical active ingredients. This new certificate provides BIOIBERICA’s Chondroitin Sulphate Sodium with the strongest guarantees given that its quality is suitably controlled by the CHONDROITIN SULPHATE SODIUM monograph Nº 2064 of the European Pharmacopoeia. Thanks to this new achievement, BIOIBERICA once again confirms its leadership as a reference company in the field of chondroprotection. (top) NEW FINDINGS ON HYAL-JOINT EFFICACY PRESENTED AT OARSI During the last World Congress of the Osteoarthritis Research Society International (OARSI) held on December 6-9, 2007 in Fort Lauderdale, Florida, BIOIBERICA presented a poster with its new findings on Hyal-Joint efficacy, which suggest that oral administration of hyaluronic acid (HA) increases HA levels in synovial fluid and could also be related to improvements in the clinical condition of affected joints. These new findings are the result of a double-blind vs. placebo trial carried out by BIOIBERICA on 12 horses with radiographic diagnosis of osteochondrosis. On Day 0 of the trial, no differences in intra-articular HA concentrations were detected between the two groups of horses. However, it was subsequently observed that HA levels increased numerically in the group treated with Hyal-Joint, but decreased in the placebo group. By Day 90, in addition to increased HA levels in the group treated with Hyal-Joint, numerical improvements were observed on the synovial-effusion scale, together with improvements in the treated horses’ degree of lameness. These results reveal a possible carry-over effect. These findings are considered to be significant because HA levels in synovial fluid usually drop in cases of osteoarthritis. (top) BIOIBERICA AT THE WORLD CONGRESS ON OSTEOARTHRITIS (OARSI) As part of its program of continued research into the efficacy of Chondroitin Sulfate (CS) in the treatment of synovitis, BIOIBERICA sponsored a symposium on The Role of Synovitis in the Physiopathology of Osteoarthritis: New Effects of Chondroitin Sulfate at the most recent World Congress on Osteoarthritis (OARSI), held in Fort Lauderdale, Florida, on December 6-9, 2007. New scientific findings indicate that the synovial membrane plays a fundamental role in the development of osteoarthritis (OA). Synovitis is an inflammatory process of the synovial membrane and constitutes the main symptom of inflammatory joint disease. In fact, the prevalence of synovitis in OA patients is 50%. Recent studies also show that the symptoms of synovitis/joint effusion are significantly reduced after 6 months’ treatment with CS. These studies attracted great interest among the international medical and scientific community. The symposium sponsored by BIOIBERICA at the OARSI confirmed the significant role of synovitis in OA, as well as its diagnosis and treatment. This most recent indication has convinced BIOIBERICA to continue its strategy of investing in CS and carrying out research into synovitis. BIOIBERICA also presented symposia on CS and synovitis at the EULAR Congress (June 2007) and the ACR Congress (November 2007). In 2008, BIOIBERICA plans to attend all the major international conferences and congresses on rheumatology and osteoarthritis. (top) |
||||
| Short News | ||
| HEPARIN
SCIENCE: NEW BIOIBERICA BUSINESS UNIT Within its process of continued expansion and growth, BIOIBERICA has created a new business unit, HEPARIN SCIENCE, whose work will focus on the development of heparin projects. The goal of the HEPARIN SCIENCE business unit is to consolidate BIOIBERICA’s position on the heparin market, the specialty that was, in fact, the reason for the company’s creation in 1975. This important new business unit is an exciting and ambitious project that will enable BIOIBERICA to maintain its leadership in the field of heparin production, in which it offers guarantees of top quality in addition to being a benchmark for the scientific community. This new organization will also enable the JOINT CARE DIVISION to specialize in joint-health projects. The consolidation of the JOINT CARE DIVISION as a strategic focal point of research and growth is a stimulating new challenge for the division. BIOIBERICA VETERINARY CONSOLIDATES ITS INTERNATIONAL POSITION: BIOIBERICA’s Veterinary Division consolidated its international position in 2007, thanks to increased sales of its products in Europe. Particularly successful was COSEQUIN, a product for animals with joint problems whose sales considerably increased compared with 2006. This growth confirms the positive results of the Veterinary Division’s increase in exports. |
||
| Latest eNews | ||
| You can read previous numbers of Joint Care
eNews online at our website: Number 4 Number 5 Number 6 Number 7 |
||
| Our Products | ||
 | ||
 |
||
 |
||
| If
you don’t want to receive any further Joint Care eNews,
please click here to unsubscribe. |
Bioiberica SA follows the Spanish Organic Law 15, 13th of Dec 1999. According to the Spanish organic law of data protection we are obliged to communicate to you that any data that you may provide to us by telephone or written will remain totally confidential in the DB of Bioiberica SA and it will only be used by Bioiberica SA, until you tell us not to continue doing so. You will always have the right to modify any of your data at any time. | ||||
 |
|
||||||||